New study tracks pregnancy safety of rare disease drug

NCT ID NCT05040373

Recruiting now Knowledge-focused Sponsor: Alnylam Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study monitors pregnancy outcomes in women who took patisiran-LNP for hereditary ATTR amyloidosis. Researchers will track birth defects, pregnancy complications, and infant health. The goal is to better understand the drug's safety during pregnancy, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY TRANSTHYRETIN-MEDIATED (HATTR) AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Amyloid Neuropathies, Familial amyloidosis familial amyloid neuropathy hereditary amyloidosis polyneuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEREDITARY TRANSTHYRETIN-MEDIATED (HATTR) AMYLOIDOSIS POLYNEUROPATHY

Contacts and locations

Locations

Clinical Trial Site
RECRUITING

Iowa City, Iowa, 52242, United States
Clinical Trial Site
RECRUITING

Nantes, France
Clinical Trial Site
RECRUITING

Münster, Germany
Clinical Trial Site
RECRUITING

Pavia, Italy
Clinical Trial Site
RECRUITING

Groningen, Netherlands
Clinical Trial Site
RECRUITING

Lisbon, Portugal
Clinical Trial Site
RECRUITING

Madrid, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.